Seegene Inc
상단으로
Contact Us

Seegene Participates in National Congress of Colposcopy and Genital Pathology in Mexico

Mar 03, 2016

?
From March 3~5, Seegene participated in the 2016 National Congress of Colposcopy and Genital Pathology in Mexico.
?
This congress is an academic conference for obstetricians, gynecologists and pathologists in Mexico,?
where attendees can share the latest information on gynecologic cancer research (including cervical cancer),
effective treatment methods, and new diagnosis techniques.
?
After Brazil, Mexico has the second largest in vitro diagnosis market in Latin America. Its diagnosis?
market is growing rapidly, especially with efforts being made on a national level for the prevention?
and early diagnosis of cervical cancer.
?
At this year’s congress, Seegene introduced two products: one which simultaneously screens for?
14 high-risk HPVs that cause cervical cancer (Anyplex™ II HPV HR Detection) and another which
tests for 28 low and high-risk HPV genotypes (Anyplex™ II HPV28 Detection). These products will
be Seegene’s stepping stone for entry into the Mexican cervical cancer market. Both products?
have already been registered with Mexico’s Secretariat of Health and are beginning to be used at?
mid- and large-sized health centers and at hospitals, The Anyplex™ II HPV HR Detection in?
particular, has been deemed “appropriate for cervical cancer screening inspections” in clinical?
evaluations conducted in accordance with international guidelines.
?
Seegene gave a presentation entitled “New Paradigm of Multiplex Real-time PCR” technology?
under the conference topic of “Recent Advances in HPV qPCR for Cervical Cancer Screening.”?
By explaining the characteristics of HPV test products that use real-time PCR technology, along with?
their usefulness in a clinical setting, Seegene gave the audience a better understanding of its?
products and generated a lot of interest.